Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Saskia Cheyne"'
Autor:
Doah Cho, Sarah J. Lord, Robyn Ward, Maarten IJzerman, Andrew Mitchell, David M. Thomas, Saskia Cheyne, Andrew Martin, Rachael L. Morton, John Simes, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized controlled trials (RCTs) are often impractical in rare diseases, leading to calls for s
Externí odkaz:
https://doaj.org/article/01054442bb48485e8ed565d3f77224e0
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
A “living” approach to clinical practice guidelines is when the identification, appraisal and synthesis of evidence is maintained and repeated at an agreed frequency, with a clear process for when and how new evidence is to be incorporated. The v
Externí odkaz:
https://doaj.org/article/fa3397f99ce541628e769a6a07f4448c
Publikováno v:
BMJ Open, Vol 12, Iss 7 (2022)
Objectives Cancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infea
Externí odkaz:
https://doaj.org/article/fb8e0d11adc14493985bdedd16769a0f
Autor:
Saskia Cheyne, David Fraile Navarro, Kelvin Hill, Steve McDonald, David Tunnicliffe, Heath White, Samuel Whittle, Justine Karpusheff, Reem Mustafa, Rebecca L. Morgan, Shahnaz Sultan, Tari Turner
Publikováno v:
Journal of Clinical Epidemiology. 155:84-96
Autor:
Saskia Cheyne, David Fraile Navarro, Amanda K. Buttery, Samantha Chakraborty, Olivia Crane, Kelvin Hill, Emma McFarlane, Rebecca L. Morgan, Reem A. Mustafa, Alex Poole, David Tunnicliffe, Joshua P. Vogel, Heath White, Samuel Whittle, Tari Turner
Publikováno v:
Journal of Clinical Epidemiology. 155:73-83
This article is part of a series on methods for living guidelines, consolidating practical experiences from developing living guidelines. It focuses on methods for identification, selection, and prioritisation of clinical questions for a living appro
Autor:
David Fraile Navarro, Saskia Cheyne, Kelvin Hill, Emma McFarlane, Rebecca L. Morgan, M. Hassan Murad, Reem A. Mustafa, Shahnaz Sultan, David J. Tunnicliffe, Joshua P. Vogel, Heath White, Tari Turner
Publikováno v:
Journal of Clinical Epidemiology. 155:118-128
Producing living guidelines requires making important decisions about methods for evidence identification, appraisal and integration to allow the living mode to function. Clarifying what these decisions are and the trade-offs between options is neces
Publikováno v:
BMJ open. 12(7)
ObjectivesCancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infeas
Autor:
Caroline Se, Homer, Vijay, Roach, Leila, Cusack, Michelle L, Giles, Clare, Whitehead, Wendy, Burton, Teena, Downton, Glenda, Gleeson, Adrienne, Gordon, Karen, Hose, Jenny, Hunt, Jackie, Kitschke, Nolan, McDonnell, Philippa, Middleton, Jeremy Jn, Oats, Antonia W, Shand, Kellie, Wilton, Joshua, Vogel, Julian, Elliott, Steven, McGloughlin, Steve J, McDonald, Heath, White, Saskia, Cheyne, Tari, Turner
Publikováno v:
The Medical journal of Australia. 217
Pregnant women are at higher risk of severe illness from coronavirus disease 2019 (COVID-19) than non-pregnant women of a similar age. Early in the COVID-19 pandemic, it was clear that evidenced-based guidance was needed, and that it would need to be
Autor:
Kylie E Hunter, Saskia Cheyne, Anna Lene Seidler, Davina Ghersi, Jesse A. Berlin, Lisa M. Askie
Publikováno v:
International Journal of Epidemiology. 50
Focus of Presentation In a prospective meta-analysis (PMA), studies are included before their results are known. This can reduce risk of publication bias and selective outcome reporting, and enables researchers to harmonise their research efforts. De
Publikováno v:
Cancer Research. 82:5963-5963
BACKGROUND: Advances in understanding of potentially targetable molecular pathways driving carcinogenesis coupled with rapid development of tumor profiling technologies are partitioning cancers into rare biomarker-defined diseases. Assessing biomarke